ClinicalTrials.gg
Not yet recruitingNCT07941479RIMOSTROKE-2Updated Nov 17, 2026

Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients

A Phase 2 interventional study of Rimonabant and Placebo in Subacute Stroke, sponsored by Sinfatin S.L. Not yet recruiting at 6 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sinfatin S.L · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 322 studies in Stroke with a site in Spain — 72 open to participants now, 90 under way, 6 of them phase 3. Stroke · Spain.

Planned enrollment
116th of 245
80 · median 70
Started
2026
with 15 others
Phase 2
15 of 322
2 open now
Primary completion
2028-01
later than 73 of 89 live
Registered
322nd of 322
by date

Among the 322 studies in Stroke with a site in Spain, this one is the 116th largest by planned enrollment of the 245 interventional ones that give a count, is one of 16 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 73 of the 89 other live ones, and was the 322nd registered.

Stroke

8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.

Browse Stroke studies →

Open to participants now

72 of the 322 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 322 studies in Stroke with a site in Spain, or all of them as a file.
02

Study summary

The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.

Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.

Read the detailed description

Stroke is a major cause of disability worldwide. Many patients experience persistent functional limitations that can affect their independence in daily activities and quality of life, despite being involved in rehabilitation programs.

The endocannabinoid system, particularly the cannabinoid type 1 (CB1) receptor, is involved in the regulation of neuronal activity and motor function. Rimonabant is a selective CB1 receptor antagonist/inverse agonist that has demonstrated effects on corticospinal excitability and motor performance in previous preclinical and clinical research.

Based on this evidence, this study aims to investigate whether treatment with low-dose rimonabant can improve functional independence in post-stroke patients during the subacute phase. RIMOSTROKE-2 is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial, to evaluate efficacy and safety of rimonabant.

The primary objective is to evaluate the effect of rimonabant on functional independence, measured by the change in the total Barthel Index (BI) score. Secondary objectives include assessing motor function, walking ability, balance, fatigue, neurological status, cognitive function and health-related quality of life. The safety and tolerability of rimonabant will also be evaluated through adverse event monitoring, clinical examinations, laboratory tests, vital signs and electrocardiogram.

The treatment period will last 90 days, followed by a 45-day follow-up period. All participants will continue to receive standard medical care and rehabilitation.

03

Conditions studied

  • Subacute Stroke

Browse trials for

Keywords

  • Rimonabant
  • CB1 receptor antagonist
  • Stroke rehabilitation
  • Functional recovery
  • Subacute stroke
  • Barthel index
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years.
  • Between 30 days and 3 months (30 - 90 days) since the stroke.
  • mRS score between 2 and 4.
  • BI score ≤ 70 at screening.
  • Capacity to provide .

Exclusion criteria

Exclusion Criteria:

  • High suicide risk assessed by C-SSRS.
  • History of severe psychiatric disorders, major depression or prior suicide attempts.
  • Treatment with anticoagulants or strong inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort).
  • Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions.
  • > 40 kg/m².
  • Pregnancy or breastfeeding.
  • Fertile men or women who cannot guarantee the use of highly effective methods, as defined by the European HMA-CTFG guidelines at least 45 days after the last dose of rimonabant -i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (CTFG, 2020).
  • Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease.
  • Known allergy to rimonabant or any of the used.
  • Participation in another clinical trial within the month prior to enrolment.
  • Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Rimonabant 5 mg

    Participants randomized to receive rimonabant 5 mg.

    Drug: Rimonabant

  • Placebo comparator
    Placebo

    Participants randomized to receive matching placebo.

    Drug: Placebo

Interventions

  • Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.

  • DrugPlacebo

    Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.

06

What researchers measure

Primary outcomes

  1. Barthel Index (BI)

    The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.

    Time frame: Baseline and end of follow-up (day 135)

Secondary outcomes

  1. Six-Minute Walk Test (6MWT)

    The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.

    Time frame: Baseline and end of follow-up (day 135)

  2. Ten-Meter Walk Test (10MWT)

    The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second.

    Time frame: Baseline and end of follow-up (day 135)

  3. Borg CR10 Scale

    The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion.

    Time frame: Baseline and end of follow-up (day 135)

  4. Fatigue Severity Scale (FSS)

    The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity.

    Time frame: Baseline and end of follow-up (day 135)

  5. Stroke Impact Scale (SIS 3.0)

    The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations.

    Time frame: Baseline and end of follow-up (day 135)

  6. Five-level EuroQol five-dimension questionnaire (EQ-5D-5L)

    The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set.

    Time frame: Baseline and end of follow-up (day 135)

  7. Patient Global Impression of Change (PGIC)

    The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change.

    Time frame: End of treatment (day 90) and End of follow-up (day 135)

  8. Adverse Events (AEs)

    Number of participants experiencing at least one adverse event (AE). Adverse events will be recorded and assessed by severity, causality, and type.

    Time frame: Baseline and end of follow-up (day 135)

  9. Serious Adverse Events (SAEs)

    Number of participants experiencing at least one serious adverse event (SAE) during the study.

    Time frame: Baseline and end of follow-up (day 135)

  10. Adverse Events of Special Interest (AESIs)

    Number of participants experiencing at least one protocol-defined adverse event of special interest. Particular attention is given to psychiatric events and clinically relevant changes in mental status because of the known psychiatric risk profile of rimonabant.

    Time frame: Baseline and end of follow-up (day 135)

  11. Beck Depression Inventory-II (BDI-II)

    The Beck Depression Inventory-II (BDI-II) assesses depressive symptoms. Higher scores indicate greater depressive symptom severity. According to the protocol, a score ≥20 triggers clinical evaluation by the investigator.

    Time frame: Baseline and end of follow-up (day 135)

  12. Hospital Anxiety and Depression Scale-Anxiety (HADS-A)

    The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) assesses anxiety symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

    Time frame: Baseline and end of follow-up (day 135)

  13. Hospital Anxiety and Depression Scale-Depression (HADS-D)

    The depression subscale of the Hospital Anxiety and Depression Scale (HADS) assesses depresive symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

    Time frame: Baseline and end of follow-up (day 135)

  14. The Visual Analogue Scale for Pain (VAS-P)

    Assesses the participant's subjective perception of pain intensity. Changes from baseline will be used to identify clinically significant changes in pain during treatment and follow-up.

    Time frame: Baseline and end of follow-up (day 135)

  15. Spasticity Assessed by Modified Ashworth Scale (MAS)

    The MAS assesses resistance to passive movement as a measure of muscle spasticity. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate category of 1+. Higher scores indicate greater spasticity.

    Time frame: Baseline and end of follow-up (day 135)

  16. Number of Falls

    Mean number of falls during the previous 30 days, based on weekly records in the participant diary and collected at each follow-up visit.

    Time frame: Baseline and end of follow-up (day 135)

  17. Timed Up and Go test (TUG)

    The TUG assesses functional mobility and fall risk by measuring the time taken to stand up from a chair, walk 3 meters, turn around, return and sit down. Longer times indicate poorer functional mobility and a higher risk of falls.

    Time frame: Baseline and end of follow-up (day 135)

  18. Berg Balance Scale (BBS)

    The BBS assesses static and dynamic balance through 14 functional tasks, providing a quantitative measure of postural control and fall risk. Higher scores indicate better balance and a lower risk of falls.

    Time frame: Baseline and end of follow-up (day 135)

  19. Fugl-Meyer Assessment - Upper Extremities (FMA-UE)

    The FMA-UE assesses upper limb motor function after stroke, evaluating movement control, coordination and reflex activity. Higher scores indicate better motor function and less severe upper limb impairment.

    Time frame: Baseline and end of follow-up (day 135)

  20. National Institutes of Health Stroke Scale (NIHSS)

    The NIHSS assesses the severity of neurological deficits after stroke by evaluating consciousness, language, motor, sensory and visual functions. Scores range from 0 to 42, with higher scores indicating greater neurological impairment and more severe stroke symptoms.

    Time frame: Baseline and end of follow-up (day 135)

  21. Modified Rankin Scale (mRS)

    The mRS assesses the degree of global disability and dependence in activities of daily living (ADL) following a neurological event. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability and dependence.

    Time frame: Baseline and end of follow-up (day 135)

  22. Montreal Cognitive Assessment (MoCA)

    The MoCA assesses global cognitive function through the evaluation of attention, memory, executive functions, language, visuospatial abilities and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Baseline and end of follow-up (day 135)

  23. Swallowing Disturbance Questionnaire (SDQ)

    The SDQ assesses the presence and severity of swallowing disorders through a self-reported questionnaire, identifying symptoms associated with dysphagia. Higher scores indicate more severe swallowing difficulties and a greater likelihood of dysphagia.

    Time frame: Baseline and end of follow-up (day 135)

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

Of 132 phase 2 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941479
Lead sponsor
Sinfatin S.L
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Antonio Oliviero, MD, PhD
Contact
antonio.oliviero@sinfatin.com
+34 646330976
Eloy Roberto Ferreras, PhD
Contact
eloy.ferreras@sinfatin.com
+34617037986

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion